Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03943342
Title Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kerry Rogers
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.